Citigroup’s Nexvet Biopharma plc Ordinary Shares NVET Stock Holding History

Citigroup’s Portfolio NVET Stock Details NVET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,500	Closed	-$21K	–	7637
2017 Q1	$21K	Buy	5,500 +300	+6%	+$1.05K	﹤0.01%	6242
2016 Q4	$19K	Sell	5,200 -500	-9%	-$2.06K	﹤0.01%	6553
2016 Q3	$24K	Hold	5,700	–	–	﹤0.01%	6122
2016 Q2	$27K	Hold	5,700	–	–	﹤0.01%	5993
2016 Q1	$19K	Hold	5,700	–	–	﹤0.01%	6581
2015 Q4	$19K	Hold	5,700	–	–	﹤0.01%	6517
2015 Q3	$21K	Buy	5,700 +4,900	+613%	+$22.3K	﹤0.01%	6017
2015 Q2	$4K	Sell	800 -800	-50%	-$5.54K	﹤0.01%	6940
2015 Q1	$13K	Buy	+1,600	New	+$15.1K	﹤0.01%	6355

Other funds holding NVET

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

KAM

Kassirer Asset Management Toronto, Ontario, Canada $4.07M AUM 49.71% 1-Year Est. Return

HCMT

Highland Capital Management (Texas) Dallas, Texas $39M AUM

Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

GCIA

Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return

GLG Partners London, United Kingdom $2.14B AUM 21.14% 1-Year Est. Return

SMC

S. Muoio & Co New York $75.7M AUM 42.51% 1-Year Est. Return

Citigroup's NVET Position: Q2 2017 in Review

Citigroup sold out of Nexvet Biopharma plc Ordinary Shares (NVET) in Q2 2017, closing a stake of 5,500 shares — an estimated $21K sold.

Citigroup first reported a position in NVET in Q1 2015 and held it in 9 quarters. The position peaked at $27K in Q2 2016. 20 funds tracked by Wall St. Rank hold NVET as of Q2 2017.

Citigroup reported no remaining Nexvet Biopharma plc Ordinary Shares position as of Q2 2017 after selling out during the quarter.
Citigroup sold 5,500 Nexvet Biopharma plc Ordinary Shares shares in Q2 2017, an estimated $21K.
Citigroup first reported a position in Nexvet Biopharma plc Ordinary Shares in Q1 2015 and held it in 9 quarters.
Citigroup's Nexvet Biopharma plc Ordinary Shares position peaked at $27K in Q2 2016.
20 funds tracked by Wall St. Rank held Nexvet Biopharma plc Ordinary Shares as of Q2 2017.

Based on Citigroup's 13F filing for Q2 2017, filed 11 Aug 2017.